

JosÃ© Sifuentes-Osornio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2195442/publications.pdf>

Version: 2024-02-01

118
papers

4,519
citations

136950

32
h-index

118850

62
g-index

128
all docs

128
docs citations

128
times ranked

6045
citing authors

#	ARTICLE	IF	CITATIONS
1	Large-scale screening for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) among healthcare workers: Prevalence and risk factors for asymptomatic and pauci-symptomatic carriers, with emphasis on the use of personal protective equipment (PPE). <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 513-517.	1.8	7
2	Outcomes of patients with severe and critical COVID-19 treated with dexamethasone: a prospective cohort study. <i>Emerging Microbes and Infections</i> , 2022, 11, 50-59.	6.5	12
3	Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID). <i>Journal of General Internal Medicine</i> , 2022, 37, 4-14.	2.6	20
4	Outbreak of NDM-1-Producing <i>Escherichia coli</i> in a Coronavirus Disease 2019 Intensive Care Unit in a Mexican Tertiary Care Center. <i>Microbiology Spectrum</i> , 2022, 10, e0201521.	3.0	6
5	NAFLD determined by Dallas Steatosis Index is associated with poor outcomes in COVID-19 pneumonia: a cohort study. <i>Internal and Emergency Medicine</i> , 2022, 17, 1355-1362.	2.0	11
6	Incidence of Cytomegalovirus disease and viral replication kinetics in seropositive liver transplant recipients managed under preemptive therapy in a tertiary-care center in Mexico City: a retrospective cohort study. <i>BMC Infectious Diseases</i> , 2022, 22, 155.	2.9	2
7	Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Rheumatology</i> , The, 2022, 4, e351-e361.	3.9	24
8	Risk Factors Associated with Failure of Linezolid Therapy in Vancomycin-Resistant <i>Enterococcus faecium</i> Bacteremia: A Retrospective Cohort Study in a Referral Center in Mexico. <i>Microbial Drug Resistance</i> , 2022, 28, 744-749.	2.0	4
9	Outcomes in Temporary ICUs Versus Conventional ICUs: An Observational Cohort of Mechanically Ventilated Patients With COVID-19-Induced Acute Respiratory Distress Syndrome. , 2022, 4, e0668.		9
10	Clinicopathologic characteristics of severe COVID-19 patients in Mexico City: A post-mortem analysis using a minimally invasive autopsy approach. <i>PLoS ONE</i> , 2022, 17, e0262783.	2.5	7
11	Understanding The Impact of ICU Personnel on ICU Mortality During Times of High Demand. <i>Annals of the American Thoracic Society</i> , 2022, , .	3.2	1
12	Accuracy of galactomannan testing on tracheal aspirates in COVID-19-associated pulmonary aspergillosis. <i>Mycoses</i> , 2021, 64, 364-371.	4.0	44
13	Low Thoracic Skeletal Muscle Area Is Not Associated With Negative Outcomes in Patients With COVID-19. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2021, 100, 413-418.	1.4	28
14	In-hospital mortality from severe COVID-19 in a tertiary care center in Mexico City; causes of death, risk factors and the impact of hospital saturation. <i>PLoS ONE</i> , 2021, 16, e0245772.	2.5	94
15	Impact of undiagnosed type 2 diabetes and pre-diabetes on severity and mortality for SARS-CoV-2 infection. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002026.	2.8	46
16	Antimicrobial Resistance Patterns and Antibiotic Use during Hospital Conversion in the COVID-19 Pandemic. <i>Antibiotics</i> , 2021, 10, 182.	3.7	31
17	Adaptive Metabolic and Inflammatory Responses Identified Using Accelerated Aging Metrics Are Linked to Adverse Outcomes in Severe SARS-CoV-2 Infection. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, e117-e126.	3.6	11
18	Diagnostic accuracy of antigen detection in urine and molecular assays testing in different clinical samples for the diagnosis of progressive disseminated histoplasmosis in patients living with HIV/AIDS: A prospective multicenter study in Mexico. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009215.	3.0	25

#	ARTICLE	IF	CITATIONS
19	Risk factors and outcomes associated with vancomycin-resistant <i>Enterococcus faecium</i> and ampicillin-resistant <i>Enterococcus faecalis</i> bacteraemia: A 10-year study in a tertiary-care centre in Mexico City. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 24, 198-204.	2.2	15
20	Genetic diversity of <i>Mycobacterium bovis</i> evaluated by spoligotyping and MIRU-VNTR in an intensive dairy cattle breeding area in Mexico. <i>Transboundary and Emerging Diseases</i> , 2021, , .	3.0	2
21	Mycobacterial Growth Inhibition Assay (MGIA) as a Host Directed Diagnostic Tool for the Evaluation of the Immune Response in Subjects Living With Type 2 Diabetes Mellitus. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 640707.	3.9	2
22	Adverse Effects Associated With the Use of Antimalarials During The COVID-19 Pandemic in a Tertiary Care Center in Mexico City. <i>Frontiers in Pharmacology</i> , 2021, 12, 668678.	3.5	3
23	Surge in Ventilator-Associated Pneumonias and Bloodstream Infections in An Academic Referral Center Converted to Treat COVID-19 Patients. <i>Revista De Investigacion Clinica</i> , 2021, 73, .	0.4	3
24	Genetic diversity and primary drug resistance transmission in <i>Mycobacterium tuberculosis</i> in southern Mexico. <i>Infection, Genetics and Evolution</i> , 2021, 93, 104994.	2.3	8
25	Association of recurrent common infections and subclinical cardiovascular disease in Mexican women. <i>PLoS ONE</i> , 2021, 16, e0246047.	2.5	1
26	The Evolutionary Landscape of SARS-CoV-2 Variant B.1.1.519 and Its Clinical Impact in Mexico City. <i>Viruses</i> , 2021, 13, 2182.	3.3	31
27	Perioperative fosfomycin disodium prophylaxis against urinary tract infection in renal transplant recipients: a randomized clinical trial. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1996-2003.	0.7	11
28	Effect of Fosfomycin on Cyclosporine Nephrotoxicity. <i>Antibiotics</i> , 2020, 9, 720.	3.7	0
29	High prevalence of MDR gram-negative bacteria in feces of healthy blood donors in Mexico. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 1439-1444.	2.9	1
30	Nontuberculous mycobacterial infection in a tertiary care center in Mexico, 2001–2017. <i>Brazilian Journal of Infectious Diseases</i> , 2020, 24, 213-220.	0.6	11
31	Latent Tuberculosis in Hematopoietic Stem Cell Transplantation: Diagnostic and Therapeutic Strategies to Prevent Disease Activation in an Endemic Population. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1350-1354.	2.0	9
32	Validation and repurposing of the MSL-COVID-19 score for prediction of severe COVID-19 using simple clinical predictors in a triage setting: The Nutri-CoV score. <i>PLoS ONE</i> , 2020, 15, e0244051.	2.5	22
33	Clinical and Epidemiological Characteristics of Patients Diagnosed with COVID-19 in a Tertiary Care Center in Mexico City: A Prospective Cohort Study. <i>Revista De Investigacion Clinica</i> , 2020, 72, 165-177.	0.4	63
34	Wuhan: Back to the Future and the Return of Coronaviruses. <i>Revista De Investigacion Clinica</i> , 2020, 72, 5-7.	0.4	1
35	Simvastatin Enhances the Immune Response Against <i>Mycobacterium tuberculosis</i> . <i>Frontiers in Microbiology</i> , 2019, 10, 2097.	3.5	31
36	Azole resistance and <i>cyp51A</i> mutation screening in <i>Aspergillus fumigatus</i> in Mexico. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2047-2050.	3.0	15

#	ARTICLE	IF	CITATIONS
37	Expression of USP18 and IL2RA Is Increased in Individuals Receiving Latent Tuberculosis Treatment with Isoniazid. <i>Journal of Immunology Research</i> , 2019, 2019, 1-13.	2.2	16
38	Enfermedad granulomatosa hepática. <i>Gaceta Medica De Mexico</i> , 2019, 155, 266-275.	0.3	0
39	Tuberculosis and systemic lupus erythematosus: a case-control study in Mexico City. <i>Clinical Rheumatology</i> , 2018, 37, 2095-2102.	2.2	16
40	Asymptomatic bacteriuria in kidney transplant recipients: The challenge in the first 8 weeks. <i>Transplant Infectious Disease</i> , 2018, 20, e12895.	1.7	3
41	Risk factors associated with prolonged hospital length-of-stay: 18-year retrospective study of hospitalizations in a tertiary healthcare center in Mexico. <i>PLoS ONE</i> , 2018, 13, e0207203.	2.5	52
42	Potential Effect of Statins on Mycobacterium tuberculosis Infection. <i>Journal of Immunology Research</i> , 2018, 2018, 1-14.	2.2	15
43	Mycobacterium tuberculosis complex bacteremia among HIV and non-HIV patients in a Mexican tertiary care center. <i>Brazilian Journal of Infectious Diseases</i> , 2018, 22, 387-391.	0.6	1
44	Diagnostic accuracy cohort study and clinical value of the Histoplasma urine antigen (ALPHA) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006872.	3.0	21
45	Antimicrobial susceptibility of gram-negative bacilli isolated from intra-abdominal and urinary-tract infections in Mexico from 2009 to 2015: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). <i>PLoS ONE</i> , 2018, 13, e0198621.	2.5	30
46	Fosfomycin trometamol in the prophylaxis of post-kidney transplant urinary tract infection: A controlled, randomized clinical trial. <i>Transplant Infectious Disease</i> , 2018, 20, e12980.	1.7	11
47	Factors associated with an outbreak of hospital-onset, healthcare facility-associated Clostridium difficile infection (HO-HCFA CDI) in a Mexican tertiary care hospital: A case-control study. <i>PLoS ONE</i> , 2018, 13, e0198212.	2.5	12
48	Genotyping and spatial analysis of pulmonary tuberculosis and diabetes cases in the state of Veracruz, Mexico. <i>PLoS ONE</i> , 2018, 13, e0193911.	2.5	9
49	First case of Nocardia amamiensis pulmonary infection in Mexico. <i>New Microbes and New Infections</i> , 2017, 16, 1-2.	1.6	4
50	Changing trends in serotypes of S. pneumoniae isolates causing invasive and non-invasive diseases in unvaccinated population in Mexico (2000-2014). <i>International Journal of Infectious Diseases</i> , 2017, 58, 1-7.	3.3	13
51	Impact of Clostridium difficile infection caused by the NAP1/RTO27 strain on severity and recurrence during an outbreak and transition to endemicity in a Mexican tertiary care center. <i>International Journal of Infectious Diseases</i> , 2017, 65, 44-49.	3.3	20
52	Drugs in Clinical Development for Fungal Infections. <i>Drugs</i> , 2017, 77, 1505-1518.	10.9	58
53	Identification and susceptibility testing of Candida spp . directly from yeast-positive blood cultures with Vitek 2. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 89, 202-204.	1.8	1
54	Acute Cholangitis After Bilioenteric Anastomosis for Bile Duct Injuries. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1613-1619.	1.7	4

#	ARTICLE	IF	CITATIONS
55	Impact of inappropriate antifungal therapy according to current susceptibility breakpoints on <i>Candida</i> bloodstream infection mortality, a retrospective analysis. <i>BMC Infectious Diseases</i> , 2017, 17, 753.	2.9	15
56	Molecular clustering of patients with diabetes and pulmonary tuberculosis: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0184675.	2.5	15
57	Clinical and Epidemiological Description of Diarrheal Episodes Caused by <i>Clostridium difficile</i> RT027 in Mexico. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
58	Associated factors and outcomes for OXA-232 Carbapenem-resistant Enterobacteriaceae infections in a tertiary care centre in Mexico City: A caseâ€“control-control study. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 86, 243-248.	1.8	8
59	Human tuberculosis caused by <i>Mycobacterium bovis</i> : a retrospective comparison with <i>Mycobacterium tuberculosis</i> in a Mexican tertiary care centre, 2000â€“2015. <i>BMC Infectious Diseases</i> , 2016, 16, 657.	2.9	35
60	Isoniazid Mono-Resistant Tuberculosis: Impact on Treatment Outcome and Survival of Pulmonary Tuberculosis Patients in Southern Mexico 1995-2010. <i>PLoS ONE</i> , 2016, 11, e0168955.	2.5	23
61	Seroprevalence of brucellosis among dairy farm workers in Mexico. <i>Salud Publica De Mexico</i> , 2016, 58, 366-370.	0.4	1
62	Trends of <i>Mycobacterium bovis</i> Isolation and First-Line Anti-tuberculosis Drug Susceptibility Profile: A Fifteen-Year Laboratory-Based Surveillance. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0004124.	3.0	34
63	Association of Pulmonary Tuberculosis and Diabetes in Mexico: Analysis of the National Tuberculosis Registry 2000â€“2012. <i>PLoS ONE</i> , 2015, 10, e0129312.	2.5	41
64	Factors Associated to Prevalence and Incidence of Carbapenem-Resistant Enterobacteriaceae Fecal Carriage: A Cohort Study in a Mexican Tertiary Care Hospital. <i>PLoS ONE</i> , 2015, 10, e0139883.	2.5	59
65	Effect of isoniazid on antigen-specific interferon- γ secretion in latent tuberculosis. <i>European Respiratory Journal</i> , 2015, 45, 473-482.	6.7	13
66	Outbreak Caused by Enterobacteriaceae Harboring NDM-1 Metallo- β -Lactamase Carried in an IncFII Plasmid in a Tertiary Care Hospital in Mexico City. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7080-7083.	3.2	56
67	Impact of ertapenem on antimicrobial resistance in a sentinel group of Gram-negative bacilli: a 6 year antimicrobial resistance surveillance study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 914-921.	3.0	8
68	Zika Virus: A New Epidemic on Our Doorstep. <i>Revista De Investigacion Clinica</i> , 2015, 67, 329-32.	0.4	15
69	Surveillance of <i>Candida</i> spp Bloodstream Infections: Epidemiological Trends and Risk Factors of Death in Two Mexican Tertiary Care Hospitals. <i>PLoS ONE</i> , 2014, 9, e97325.	2.5	30
70	Results of the Implementation of a Pilot Model for the Bidirectional Screening and Joint Management of Patients with Pulmonary Tuberculosis and Diabetes Mellitus in Mexico. <i>PLoS ONE</i> , 2014, 9, e106961.	2.5	28
71	Primary prophylaxis with ciprofloxacin in cirrhotic patients with ascites: a randomized, double blind study. <i>Annals of Hepatology</i> , 2014, 13, 65-74.	1.5	3
72	Diagnosis and Treatment of Non-European Fungal Infections. <i>Current Fungal Infection Reports</i> , 2014, 8, 343-352.	2.6	2

#	ARTICLE	IF	CITATIONS
73	Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis. <i>Clinical Infectious Diseases</i> , 2014, 59, 1364-1374.	5.8	116
74	Sir3 Polymorphisms in <i>Candida glabrata</i> Clinical Isolates. <i>Mycopathologia</i> , 2013, 175, 207-219.	3.1	11
75	Genetic variations in toll-like receptor 4 in Mexican-Mestizo patients with intra-abdominal infection and/or pneumonia. <i>Immunology Letters</i> , 2013, 153, 41-46.	2.5	7
76	Prevalence of Pneumococcal Disease, Serotype Distribution, and Antimicrobial Susceptibility in Mexican Children Younger than 5 Years of Age. <i>Archives of Medical Research</i> , 2013, 44, 142-150.	3.3	14
77	Impact of cigarette smoking on rates and clinical prognosis of pulmonary tuberculosis in Southern Mexico. <i>Journal of Infection</i> , 2013, 66, 303-312.	3.3	20
78	Prevalence of Latent and Active Tuberculosis among Dairy Farm Workers Exposed to Cattle Infected by <i>Mycobacterium bovis</i> . <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2177.	3.0	57
79	Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. <i>Thorax</i> , 2013, 68, 214-220.	5.6	221
80	Epidemiology of Candidemia in Latin America: A Laboratory-Based Survey. <i>PLoS ONE</i> , 2013, 8, e59373.	2.5	267
81	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. <i>PLoS Medicine</i> , 2012, 9, e1001300.	8.4	430
82	Tuberculosis in ageing: high rates, complex diagnosis and poor clinical outcomes. <i>Age and Ageing</i> , 2012, 41, 488-495.	1.6	58
83	Epidemiology of Invasive Fungal Infections in Latin America. <i>Current Fungal Infection Reports</i> , 2012, 6, 23-34.	2.6	85
84	Increasing prevalence of extended-spectrum-beta-lactamase among Gram-negative bacilli in Latin America – 2008 update from the Study for Monitoring Antimicrobial Resistance Trends (SMART). <i>Brazilian Journal of Infectious Diseases</i> , 2011, 15, 34-39.	0.6	20
85	Risk factors for infections requiring hospitalization in renal transplant recipients: a cohort study. <i>International Journal of Infectious Diseases</i> , 2011, 15, e188-e196.	3.3	20
86	Increasing prevalence of extended-spectrum-beta-lactamase among Gram-negative bacilli in Latin America: 2008 update from the Study for Monitoring Antimicrobial Resistance Trends (SMART). <i>Brazilian Journal of Infectious Diseases</i> , 2011, 15, 34-39.	0.6	10
87	Increasing prevalence of extended-spectrum-beta-lactamase among Gram-negative bacilli in Latin America–2008 update from the Study for Monitoring Antimicrobial Resistance Trends (SMART). <i>Brazilian Journal of Infectious Diseases</i> , 2011, 15, 34-9.	0.6	30
88	Concordance Between Two Enzyme Immunoassays for the Detection of <i>Clostridium difficile</i> Toxins. <i>Archives of Medical Research</i> , 2010, 41, 92-96.	3.3	6
89	Salvaging diabetic foot through debridement, pressure alleviation, metabolic control, and antibiotics. <i>Wound Repair and Regeneration</i> , 2010, 18, 567-571.	3.0	0
90	Tracing the Source of an Outbreak of Methicillin-Resistant <i>Staphylococcus aureus</i> in a Tertiary-Care Oncology Hospital by Epidemiology and Molecular Methods. <i>Microbial Drug Resistance</i> , 2010, 16, 203-208.	2.0	6

#	ARTICLE	IF	CITATIONS
91	Contamination of intravenous fluids: A continuing cause of hospital bacteremia. American Journal of Infection Control, 2010, 38, 217-221.	2.3	41
92	Virulence, immunopathology and transmissibility of selected strains of <i>Mycobacterium tuberculosis</i> in a murine model. Immunology, 2009, 128, 123-133.	4.4	75
93	Genotyping of the MTL loci and susceptibility to two antifungal agents of <i>Candida glabrata</i> clinical isolates. Memorias Do Instituto Oswaldo Cruz, 2009, 104, 775-782.	1.6	4
94	Molecular Analysis of <i>Mycobacterium tuberculosis</i> Strains with an Intact <i>pks15/1</i> Gene in a Rural Community of Mexico. Archives of Medical Research, 2008, 39, 809-814.	3.3	13
95	Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum β -lactamase-producing <i>Klebsiella pneumoniae</i> . International Journal of Infectious Diseases, 2008, 12, 653-659.	3.3	49
96	Vancomycin-resistant Enterococci, Mexico City. Emerging Infectious Diseases, 2007, 13, 798-799.	4.3	18
97	Screening for Tuberculosis in the Study of the Living Renal Donor in a Developing Country. Transplantation, 2006, 81, 290-292.	1.0	25
98	Global Phylogeny of <i>Mycobacterium tuberculosis</i> Based on Single Nucleotide Polymorphism (SNP) Analysis: Insights into Tuberculosis Evolution, Phylogenetic Accuracy of Other DNA Fingerprinting Systems, and Recommendations for a Minimal Standard SNP Set. Journal of Bacteriology, 2006, 188, 759-772.	2.2	381
99	Is tuberculin skin testing useful to diagnose latent tuberculosis in BCG-vaccinated children?. International Journal of Epidemiology, 2006, 35, 1447-1454.	1.9	17
100	Population Genetics Study of Isoniazid Resistance Mutations and Evolution of Multidrug-Resistant <i>Mycobacterium tuberculosis</i> . Antimicrobial Agents and Chemotherapy, 2006, 50, 2640-2649.	3.2	364
101	Molgramostim (GM-CSF) Associated With Antibiotic Treatment in Nontraumatic Abdominal Sepsis. Archives of Surgery, 2006, 141, 150.	2.2	54
102	Identification of the infectious source of an unusual outbreak of histoplasmosis, in a hotel in Acapulco, state of Guerrero, Mexico. FEMS Immunology and Medical Microbiology, 2005, 45, 435-441.	2.7	35
103	Changes in the geographical distribution of tuberculosis patients in Veracruz, Mexico, after reinforcement of a tuberculosis control programme. Tropical Medicine and International Health, 2005, 10, 305-311.	2.3	16
104	Role of <i>embB</i> Codon 306 Mutations in <i>Mycobacterium tuberculosis</i> Revisited: a Novel Association with Broad Drug Resistance and IS <i>6110</i> Clustering Rather than Ethambutol Resistance. Antimicrobial Agents and Chemotherapy, 2005, 49, 3794-3802.	3.2	103
105	Does DOTS work in populations with drug-resistant tuberculosis?. Lancet, The, 2005, 365, 1239-1245.	13.7	78
106	Tuberculosis and Diabetes in Southern Mexico. Diabetes Care, 2004, 27, 1584-1590.	8.6	182
107	Nested Polymerase Chain Reaction for <i>Mycobacterium tuberculosis</i> DNA Detection in Aqueous and Vitreous of Patients with Uveitis. Archives of Medical Research, 2003, 34, 116-119.	3.3	63
108	Rapid identification and susceptibility testing of <i>Mycobacterium tuberculosis</i> from MGIT cultures with luciferase reporter mycobacteriophages. Journal of Medical Microbiology, 2003, 52, 557-561.	1.8	52

#	ARTICLE	IF	CITATIONS
109	Tuberculosis-Related Deaths within a Well-Functioning DOTS Control Program. <i>Emerging Infectious Diseases</i> , 2002, 8, 1327-1333.	4.3	40
110	Inadequate Therapy and Antibiotic Resistance. Risk Factors for Mortality in the Intensive Care Unit. <i>Archives of Medical Research</i> , 2002, 33, 290-294.	3.3	36
111	Comparison of ceftibuten vs. amoxicillin/clavulanic acid as antibiotic prophylaxis in cholecystectomy and/or biliary tract surgery. <i>Journal of Gastrointestinal Surgery</i> , 2000, 4, 606-610.	1.7	6
112	Clinical Consequences and Transmissibility of Drug-Resistant Tuberculosis in Southern Mexico. <i>Archives of Internal Medicine</i> , 2000, 160, 630-6.	3.8	87
113	Bloodborne Viral Infections in Patients Attending an Emergency Room in Mexico City: Estimate of Seroconversion Probability in Healthcare Workers After an Occupational Exposure. <i>Infection Control and Hospital Epidemiology</i> , 2000, 21, 600-602.	1.8	16
114	Epidemiological and Biological Characteristics of Methicillin-Resistant Staphylococcal Infections in a Mexican Hospital. <i>Archives of Medical Research</i> , 1999, 30, 325-331.	3.3	10
115	Nocardiasis in Patients with HIV Infection. <i>AIDS Patient Care and STDs</i> , 1998, 12, 825-832.	2.5	27
116	Mycobacterial Infection in Mexican AIDS Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1996, 11, 53-58.	0.3	7
117	Efficacy and safety of norfloxacin versus carbenicillin indanyl sodium in the treatment of bacterial prostatitis. <i>Current Therapeutic Research</i> , 1993, 53, 154-158.	1.2	1
118	Investigación sobre epidemiología convencional y molecular de tuberculosis en Orizaba, Veracruz, 1995-2008. <i>Salud Publica De Mexico</i> , 0, 51, .	0.4	2